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ABSTRACT 
 
Objective: To describe contemporary patient characteristics and treatment patterns, 
including antithrombotic management, of post-myocardial infarction (MI) stable coronary 
artery disease (CAD) patients at high atherothrombotic risk from different geographical 
regions. 
Methods: Patients ≥50 years with prior MI 1-3 years ago and ≥1 risk factor (age ≥65 
years, diabetes, 2nd prior MI>1 yr ago, multivessel CAD, creatinine clearance 15-<60 
mL/min) were enrolled by 369 physicians (96% cardiologists) in 25 countries (2013-14) 
in the prospective TIGRIS study (NCT01866904). 
Results: 9,225 patients were enrolled (median 1.8 years) post-MI: 52% with prior ST- 
elevation MI, median age 67 years, 24% women, 67% caucasian, 55% had ≥2 
additional qualifying risk factors, 14% current smokers, 67% overweight/obese, 34% 
with blood pressure ≥140/90 mm Hg.  81% underwent percutaneous coronary 
intervention (PCI; 66% with drug-eluting stents) for the index MI.  75% of patients had 
been discharged on dual antiplatelet therapy (DAPT; acetylsalicylic acid [ASA]+ADP 
receptor inhibitor [ADPri]), mainly clopidogrel (75%).  63% had discontinued antiplatelet 
treatment (60% ADPri) around 1 year, most commonly by physician recommendation 
(90%).  At enrolment, 97% were taking an antithrombotic drug, most commonly ASA 
(88%), with 27% on DAPT (median duration 1.6 years); continued DAPT>1 year was 
highest (39%) in Asia-Pacific and lowest (12%) in Europe. 
Conclusions: Despite guideline recommendations, 1 in 4 post-MI patients did not 
receive DAPT for ~1 year.  In contrast to guideline recommendations supporting newer 
ADPris, clopidogrel was mainly prescribed.  Prior to recent RCT data supporting 
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DAPT>1 year post-MI/PCI, >1 in 4 patients have continued on DAPT, though with 
substantial international variability. 
 
Word count: 251 
Key words: antiplatelet therapy; myocardial infarction  
TIGRIS Baseline Results Manuscript January 16 2017 
 
4 
 
Coronary artery disease (CAD) is the leading cause of death worldwide and is 
increasing as a result of population growth, the aging population, and epidemiological 
changes in disease.1  The early treatment and risks of death, myocardial infarction (MI), 
and stroke have been well characterized following presentation with an acute coronary 
syndrome (ACS),2-7 particularly among those participating in randomized clinical trials 
(RCTs).8-13  However, the later management of atherothrombotic risk factors, quality of 
life, and outcomes of a contemporary stable CAD (including post-MI) patient population 
from different geographic regions and non-RCT cohorts remain less clearly defined.14-20 
Thus, the long Term rIsk, clinical manaGement and healthcare Resource utilization of 
stable coronary artery dISease (TIGRIS) study was designed to better understand the 
course of stable CAD patients 1-3 years post-MI in routine clinical practice. Specifically, 
TIGRIS aims to provide contemporary data on patient characteristics, treatment 
patterns, the burden of disease events such as cardiovascular (CV) death, recurrent MI, 
stroke, and associated CV-related healthcare resource utilization, and patient-reported 
quality of life from different geographical regions in an observational (‘real world’) patient 
population at high atherothrombotic risk.  The objective of the current analyses was to 
describe contemporary patient characteristics and treatment patterns, including 
guideline-recommended dual antiplatelet therapy, of high atherothrombotic risk patients 
from different geographical regions. 
 
METHODS 
Stable CAD patients aged 50 years or older with a documented history of 
presumed spontaneous MI, with their most recent MI occurring 1 to 3 years prior to 
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enrolment,  providing informed written consent, and with at least 1 of the following risk 
factors, were included: (a) age ≥ 65 years; (b) diabetes mellitus requiring medication; (c) 
documented history of a second prior presumed spontaneous MI (>1 year prior to 
enrolment); (d) documented history of angiographic evidence of multivessel CAD; 
and/or (e) chronic, non-end stage renal dysfunction (creatinine clearance calculated by 
Cockcroft Gault equation 15 mL/min to <60 mL/min). 
Patients were not eligible to participate if any of the following exclusion criteria 
were present: (a) presence of any condition/circumstance which, in the opinion of the 
investigator, could significantly limit the complete follow up of the patient; (b) presence 
of serious/severe co-morbidities which could limit life expectancy (<1 year); (c) ongoing 
participation in a blinded randomized clinical trial such that specific treatment(s) were 
not identifiable; and/or (d) patients receiving treatment of ticagrelor beyond 12 months 
post-MI (or off-label use of ticagrelor). 
The study was conducted in compliance with the principles of the Declaration of 
Helsinki, International Conference on Harmonisation (ICH) Good Clinical Practice 
guidelines, and applicable legislation on non-interventional studies in participating 
countries. The study protocol and informed consent was reviewed and approved by the 
corresponding health authorities and ethics boards for all participating study sites.  The 
study was registered at Clinical Trials.gov (clinical trial identifier NCT01866904). 
Data entry was completed through a standardized electronic case report form 
(eCRF).  Baseline data included relevant medical history, demographics, details 
regarding the index MI that occurred 1-3 years before enrollment, variables from routine 
physical examination and existing routine laboratory testing where available if 
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performed within 3 months prior to, and up to 1 month following, the initial visit.  In 
addition, medication use at baseline and healthcare resource utilization related to CV or 
bleeding events during the 6 months preceding enrolment were captured in the eCRF. 
The EuroQol Research foundation survey instrument for measuring self-reported 
health status in 5 dimensions (EQ-5D™; mobility, self-care, usual activities, pain or 
discomfort, anxiety or depression) with 3 levels of severity (none, moderate, severe)21;22 
was completed by the subject during the baseline visit.   
 Recruitment of sites was based upon recommendations by national principal 
investigators; the vast majority of the 349 recruiting physicians were cardiologists 
(n=334; 95.7%), internists (n=10; 2.8%), or other specialists (n=2; 0.6%), with a minority 
from general practice (n=3; 0.9%). 
 TIGRIS is a descriptive observational study with no formal hypothesis testing of 
the primary and secondary objectives. The sample size was initially estimated at 10,170 
patients, assuming a 3-year event rate of approximately 5-10%; this would allow the 
potential to describe an expected ischemic or bleeding event rate between 5% and 10% 
with a two- sided 95% confidence interval that would extend in ± 0.4% and ± 0.6% from 
the observed proportions, respectively.  Patients will be followed prospectively for 
approximately 2 years.  
The descriptive baseline analyses were conducted according to a pre-defined 
statistical analysis plan.  Categorical data are expressed as frequencies and 
percentages.  Continuous data are summarized by medians (25th and 75th percentiles).  
The proportions of patients in different geographic regions receiving antithrombotic 
treatments were compared using chi-squared tests; a p-value <0.05 was considered 
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significant but no adjustments were made for multiple comparisons.  Statistical analysis 
was performed using SAS software version 9.4 and Enterprise Guide software version 
6.1 (SAS Institute Inc., Cary, NC). 
 
RESULTS 
Patient Population 
From June 18, 2013 to November 29, 2014, 9,225 patients were enrolled by 369 
principal investigators in 25 countries from Asia-Pacific/Australia (Australia, China, 
Japan, India and South Korea [n=2,850; 31%]), Europe (Germany, Spain, Netherlands, 
Italy, Romania, Denmark, United Kingdom, Turkey, Belgium, Portugal, Finland, Norway 
and France [n=4,240; 46%]), and North (United States and Canada [n=1,024; 11%]) 
and South America (Argentina, Colombia, Brazil, Venezuela and Mexico [n=1,111, 
12%]).   Eligible patients were 50 years of age or older, with a prior MI occurring 1-3 
years before inclusion in the registry, and at least one additional risk factor (age ≥65 
years [62.5%]; diabetes mellitus requiring medication [30.4%]; second prior MI >1 year 
ago [10.2%]; multivessel CAD [65.6%]; chronic, non-end stage renal dysfunction 
[7.7%]).  More than half the patient population had 2 or more additional risk factors: 1 
qualifying risk factor (44.8%), 2 (37.8%), 3 (14.0%), 4 (2.9%), and 5 (0.4%). 
Selected patient demographics are also listed in Table 1, including by 
geographical region.  The median age was 67 (25th, 75th percentiles: 60, 73) years, 
including 1,839 patients (19.9%) who were 75 years of age or older.   Women 
represented 24.2% of the population.  The majority of patients were caucasian (66.6%); 
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27.5% were asian/oriental, 1.0% were black, and 4.8% described another race.  At 
baseline, 14.0% were current smokers. 
Table 1 – Selected demographics and medical history by geographic region  
  Total 
population 
Asia-
Pacific/Australia 
Europe North 
America 
South 
America 
Number of 
patients 
9225 (100) 2850 (30.9) 4240 
(46.0) 
1024 
(11.1) 
1111 
(12.0) 
Inclusion Risk 
Factors 
 
  Age ≥65 years 
5766 (62.5) 1652 (58.0) 
2814 
(66.4) 
666 
(65.0) 
634 
(57.1) 
Diabetes 
requiring 
medication 
2805 (30.4) 999 (35.1) 
1118 
(26.4) 
307 
(30.0) 
381 
(34.3) 
 2nd Prior MI 
943 (10.2) 210 (7.4) 491 (11.6) 
131 
(12.8) 
111 
(10.0) 
  Multivessel CAD 
6052 (65.6) 1921 (67.4) 
2714 
(64.0) 
715 
(69.8) 
702 
(63.2) 
Creatinine 
Clearance 15-60 
ml/min 
707 (7.7) 212 (7.4) 327 (7.7) 78 (7.6) 90 (8.1) 
Age, years* 
67 (60-73) 66 (59-73) 68 (62-73) 
68 (61-
74) 
66 (59-
73) 
Women 2230 (24.2) 616 (21.6) 978 (23.1) 320 
(31.3) 
316 
(28.4) 
Hypertension 6663 (72.2) 1934 (67.9) 3014 
(71.1) 
847 
(82.7) 
868 
(78.1) 
Hyperlipidemia 6147 (66.6) 1386 (48.6) 3024 
(71.3) 
927 
(90.5) 
810 
(72.9) 
Smoking status  
Current smoker 
1288 (14.0) 468 (16.4) 595 (14.0) 
123 
(12.0) 
102 (9.2) 
Former smoker 
4482 (48.6) 1194 (41.9) 
2201 
(51.9) 
505 
(49.3) 
582 
(52.4) 
Never smoker 
3453 (37.4) 1187 (41.7) 
1443 
(34.0) 
396 
(38.7) 
427 
(38.4) 
Diabetes Mellitus 3076 (33.3) 1079 (37.9) 1246 
(29.4) 
348 
(34.0) 
403 
(36.3) 
Type I 88 (2.9) 48 (4.5) 29 (2.3) 7 (2.0) 4 (1.0) 
Type II 2928 (95.2) 989 (91.7) 1201 
(96.4) 
339 
(97.4) 
399 
(99.0) 
Unknown 60 (2.0) 42 (3.9) 16 (1.3) 2 (0.6) 0 (0) 
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If type II-
Management+ 
 
Diet only 253 (8.6) 73 (7.4) 119 (9.9) 39 (11.5) 22 (5.5) 
Oral 
hypoglycemic 
2293 (78.3) 812 (82.1) 921 (76.7) 
226 
(66.7) 
334 
(83.7) 
Insulin 
798 (27.3) 205 (20.7) 359 (29.9) 
125 
(36.9) 
109 
(27.3) 
History of PCI 7913 (85.8) 2584 (90.7) 3598 
(84.9) 
836 
(81.6) 
895 
(80.6) 
History of CABG  1314 (14.2) 181 (6.4) 663 (15.6) 263 
(25.7) 
207 
(18.6) 
Chronic angina 90 (1.0) 12 (0.4) 54 (1.3) 20 (2.0) 4 (0.4) 
Heart failure 937 (10.2) 273 (9.6) 472 (11.1) 82 (8.0) 110 (9.9) 
Atrial fibrillation 1061 (11.5) 237 (8.3) 569 (13.4) 117 
(11.4) 
138 
(12.4) 
ICD 748 (8.1) 150 (5.3) 420 (9.9) 133 
(13.0) 
45 (4.1) 
Pacemaker 198 (2.2) 28 (1.0) 104 (2.5) 59 (5.8) 7 (0.6) 
TIA 211 (2.3) 32 (1.1) 131 (3.1) 34 (3.3) 14 (1.3) 
Stroke 204 (2.2) 37 (1.3) 113 (2.7) 39 (3.8) 15 (1.4) 
Peripheral 
vascular disease 
413 (4.5) 123 (4.3) 189 (4.5) 58 (5.7) 43 (3.9) 
Prior 
cerebrovascular 
revascularization 
616 (6.7) 107 (3.8) 358 (8.4) 94 (9.2) 57 (5.1) 
VTE 151 (1.6) 26 (0.9) 93 (2.2) 25 (2.4) 7 (0.6) 
Valve 
repair/replacement 
104 (1.1) 13 (0.5) 64 (1.5) 16 (1.6) 11 (1.0) 
COPD 670 (7.3) 135 (4.7) 384 (9.1) 96 (9.4) 55 (5.0) 
Chronic anemia 272 (3.0) 54 (1.9) 147 (3.5) 49 (4.8) 22 (2.0) 
Cancer 626 (6.8) 124 (4.4) 330 (7.8) 131 
(12.8) 
41 (3.7) 
Peptic ulcer 298 (3.2) 79 (2.8) 167 (3.9) 31 (3.0) 21 (1.9) 
Severe liver 
disease 
36 (0.4) 10 (0.4) 19 (0.5) 5 (0.5) 2 (0.2) 
Esophageal 
varices 
18 (0.2) 2 (0.1) 5 (0.1) 8 (0.8) 3 (0.3) 
Major bleeding# 261 (2.8) 45 (1.6) 138 (3.3) 43 (4.2) 35 (3.2) 
All numbers are given as numbers (%), except *median (25th, 75th percentiles) 
+ Oral hypoglycemic agent(s) and insulin use are not mutually exclusive 
CABG=Coronary Artery Bypass Graft surgery; CAD=Coronary Artery Disease; 
COPD=Chronic Obstructive Pulmonary Disease; ICD=Implantable Cardioverter Defibrillator; 
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PCI=Percutaneous Coronary Intervention; TIA=Transient Ischaemic Attack; VTE=Venous 
Thromboembolism;  
# that required hospitalization or urgent medical care, and/or blood transfusion and/or caused 
haematocrit drop 
 
A minority reported no formal education (4.0%), with 30.6% having 1-9 years, 
31.5% having 10-12 years, 17.6% having 13-15 years, and 16.2% having 16 or more 
years of education.  The majority lived in a metropolitan area (64.8%), 99% reported 
home as type of residence, with only 13.6% living alone. 
The majority of patients were retired (57.8%), with 25.6% working, 5.5% working 
as a homemaker, 4.9% were unemployed, and 4.4% were on sick/disability leave.  
Household income (U.S. dollars/month) was reported by half of the study population 
(n=4766, 51.7%) and was less than or equal to $1,250 for 49.2% of patients, $1,251-
5,000 for 37.1%, and >$5,000 for 13.7%.  Health care insurance status (among the 
98.7% of patients who responded) included: government (62.9%), private (19.4%), 
employer-provided (3.5%), other (4.8%), and none (5.5%). 
Index Myocardial Infarction 
The median time from the index MI to enrolment in the study was 1.8 (1.3, 2.4) 
years.  ST-segment elevation MI (STEMI) had occurred in 52.1%, non-ST-segment 
elevation MI (NSTEMI) in 41.8%, and in 6.1% the index MI type was unknown.  
Management at the time of the index MI included percutaneous coronary intervention 
(PCI; 80.0%), coronary artery bypass surgery (CABG; 7.4%), or medical treatment only 
(12.6%)(Table 2).  Compared to NSTEMI patients, a significantly greater proportion of 
STEMI patients underwent PCI (71.9% vs. 88.0%); however, fewer STEMI patients 
underwent CABG (11.6% vs. 3.6%) or received medical management only (16.5% vs. 
8.4%). 
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Table 2 – Coronary revascularization during the index myocardial infarction by 
geographical region 
  Total 
population 
Asia-
Pacific/ 
Australia 
Europe North 
America 
South 
America 
Number of patients 
9225 (100) 2850 (30.9) 4240 (46.0) 1024 (11.1) 
1111 
(12.0) 
Percutaneous 
Coronary Intervention 7376 (80.0) 2472 (86.7) 3358 (79.2) 747 (72.9) 799 (71.9) 
Drug-Eluting Stent 
4146 (56.2) 1750 (70.8) 1753 (52.2) 414 (55.4) 229 (28.7) 
Bare Metal Stent 
1476 (20.0) 267 (10.8) 730 (21.7) 159 (21.3) 320 (40.1) 
Both stent types 
59 (0.8) 13 (0.5) 34 (1.0) 9 (1.2) 3 (0.4) 
No stent 
207 (2.8) 42 (1.7) 118 (3.5) 19 (2.5) 28 (3.5) 
Unknown/incomplete 
type 1488 (20.2) 400 (16.2) 723 (21.5) 146 (19.5) 219 (27.4) 
Coronary artery 
bypass surgery 678 (7.4) 98 (3.4) 332 (7.8) 143 (14) 105 (9.5) 
All numbers are given as numbers (%) 
 
Physical and Laboratory Findings 
Physical examination findings at baseline, including by geographical region, are 
listed in SupplementaryTable 1.  Body Mass Index was (BMI) was a median of 27 (24, 
30) kg/m2), with 43.4% in the overweight and 24.2% in the obese range, respectively.  
Waist circumference was a median 97 (89, 106) cm.  The Asia-Pacific region had the 
lowest proportion of overweight/obese patients and the lowest waist circumference.  
Median resting heart rate was 68 (60, 75) beats/minute; the Asia-Pacific region had the 
highest heart rate.  Median systolic and diastolic blood pressures (BP) were 130 (120, 
140) and 77 (70, 82) mm Hg, respectively; the European region had the highest 
baseline systolic BP; 29% with a history of hypertension and 18.9% without a prior 
history of hypertension had a blood pressure ≥140/90 mm Hg.   
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Laboratory Values 
Serum hemoglobin was available in 2,810 patients from existing routine 
laboratory testing (≤3 months prior to or ≤1 month following the initial visit) and was a 
median of 13.9 (12.8, 15.0) g/dL.  Serum creatinine was available in 3,285 patients and 
was a median of 0.97 (0.83, 1.17) mg/dL; 2.5% had an estimated creatinine clearance 
(CrCl) of <30 ml/min/1.73 m2, with 19.2% having a CrCl of 30-60 ml/min/1.73 m2, and 
78.4% having a CrCl of >60 ml/min/1.73 m2, respectively.  Median fasting glucose was 
106 (94, 127) mg/dL (n=2,034) and hemoglobin A1c was 6.3 (5.8, 7.0)% (n=1,565), 
including in patients with diabetes: 132 (111, 164) mg/dL (n=731) and 6.9 (6.4, 7.7)% 
(n=821), respectively.  Total cholesterol (n=2,954), fasting low-density lipoprotein (LDL; 
n=2,027), high-density lipoprotein (n=2,871), and fasting triglycerides (n=2,123), were 
151 (131, 176), 78 (63, 99), 45 (38, 54), and 115 (86, 157) mg/dL, respectively.  The 
proportion of patients with a fasting LDL <70 mg/dL was 37%. 
Antithrombotic Therapy 
 Antithrombotic therapy prescribed at hospital discharge following the index MI 
included: single antiplatelet therapy in 21.3% (ASA 14.5%, adenosine-diphosphate 
[ADP] receptor inhibitor 6.8%), dual antiplatelet therapy (DAPT) in 74.9% (clopidogrel 
55.8%, prasugrel 10.7%, ticagrelor 7.9%, or ticlopidine 0.1%), and oral anticoagulant 
therapy in 5.5%. 
Post-MI Discontinuation 
Antithrombotic therapy prescribed following the index MI and discontinued prior 
to enrolment (n=5,868; 63.6%) included antiplatelet (62.8%) and anticoagulant (2.5%) 
treatment.  Antiplatelet therapy discontinued was primarily an ADP receptor inhibitor: 
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clopidogrel (40.3%), prasugrel (10.1%), ticagrelor (9.0%), or ticlopidine (0.2%).  ADP 
receptor inhibitor therapy was discontinued around 1 year for clopidogrel (median of 370 
[353, 424] days), prasugrel (367 [363, 397]), and ticagrelor (365 [356, 372]) and around 
6 months for ticlopidine (201 [103, 280]).  The most commonly reported reason for ADP 
receptor inhibitor cessation was the patient’s physician’s recommendation 
(89.6%)(Supplementary Table 2). 
Post-MI Continuation 
 At study enrolment, 97% of patients were taking an antithrombotic (antiplatelet 
or anticoagulant) agent (Table 3 and Figure 1), with modest differences between 
regions (Asia-Pacific lowest at 95.8% and South America highest at 98.7%).  
Antiplatelet therapy was being used in 94.2%, most commonly ASA (88.0%). Single 
antiplatelet therapy included ASA in 61.6%, and ADP receptor inhibitor in 5.7%, and 
other in 0.1%.  Dual antiplatelet therapy (DAPT) use was 26.8%, including 24.0% on 
ASA and clopidogrel and 2.4% on ASA and prasugrel (ticagrelor use was an exclusion 
criterion).  The median duration of DAPT amongst those started at the time of the index 
MI and continued until the time of enrolment was 592 (444-807) days.  There was 
substantial variation across geographic region with the lowest use of ASA alone (43.1%) 
and the highest rate of DAPT (39.4%) in Asia-Pacific and the highest use of ASA alone 
(74.8%) together with the lowest rate of DAPT (12.2%) in Europe.  Anticoagulant 
therapy was used in 594 (6.4%) at study entry.   
Table 3 – Antithrombotic treatment at enrolment by geographic region 
 Total 
population 
Asia-
Pacific 
Europe North 
America 
South 
America 
P-
value 
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Number of patients 9225 2850 4240 1024 1111  
Any antithrombotic 
therapy 
8949 
(97.0) 
2729 
(95.8) 
4134 
(97.5) 
990 
(96.7) 
1096 
(98.7) 
<0.001 
Any antiplatelet 
therapy 
8693 
(94.2) 
2701 
(94.8) 
3932 
(92.7) 
971 
(94.8) 
1089 
(98.0) 
<0.001 
Use of antiplatelet 
therapy 
 <0.001 
Single       
ASA 
5681 
(61.6) 
1229 
(43.1) 
3170 
(74.8) 
578 
(56.5) 704 (63.4) 
 
Clopidogrel 499 (5.4) 246 (8.6) 154 (3.6) 63 (6.2) 36 (3.2) 
 
Prasugrel 29 (0.3) 12 (0.4) 12 (0.3) 4 (0.4) 1 (0.1) 
 
Ticagrelor Exclusion criterion  
Other* 7 (0.1) 4 (0.1) 3 (0.1) 0 (0) 0 (0) 
 
Dual (DAPT)   
ASA + 
Clopidogrel 
2222 
(24.1) 
1122 
(39.4) 517 (12.2) 
252 
(24.6) 331 (29.8) 
 
ASA + Prasugrel 221 (2.4) 64 (2.3) 72 (1.7) 71 (6.9) 14 (1.3) 
 
ASA + Other 26 (0.3) 17 (0.6) 3 (0.1) 3 (0.3) 3 (0.3) 
 
Oral anticoagulant** 589 (6.4) 135 (4.7) 351 (8.3) 78 (7.6) 25 (2.3) 
<0.001 
Parenteral 
anticoagulant*** 8 (0.1) 2 (0.1) 6 (0.1) 0 (0) 0 (0) 
 
All numbers are given as numbers (%) 
*Other: cilostazol, sarpogrelate, dipyridamole ± ASA, trifusal, and carbasalate calcium 
**Oral anticoagulant: warfarin, acenocumarol, phenprocoumon; dabigatran, rivaroxaban, 
apixaban 
***Parenteral anticoagulant: heparin, certoparin, enoxaparin, dalteparin, or tinzaparin 
  
Other Medical Therapy 
 Other selected medical treatments at enrolment are listed in Table 4 and 
included: beta-blocker (79.9%), angiotensin converting enzyme (ACE) inhibitor (47.9%), 
angiotensin receptor blocker (ARB; 29.2%), statin (92.8%), other lipid-lowering (9.4%), 
diuretic (25.4%), and antidepressant (7.0%) therapy.  Beta-blocker use was highest in 
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South America (86.7%) and lowest in Asia-Pacific (70.9%).  ACE or ARB use was 
highest in Europe (80.9%) and lowest in North America (71.5%).  While statin use was 
uniformly high (≥92%) across all geographic regions, other lipid-lowering therapy was 
highest in North America (15.6%). Among patients with diabetes (n=2,805), 81.8% of 
those with Type II diabetes were on at least one oral hypoglycemic drug and 28.5% 
were on insulin. 
Table 4 – Selected medical therapy at enrolment by geographic region 
 Total 
population 
Asia-
Pacific/Australia 
Europe North 
America 
South 
America 
Number of patients 9113 2790 4203 1020 1100 
Beta-blocker 7284 (79.9) 1977 (70.9) 3516 
(83.7) 
837 
(82.1) 
954 
(86.7) 
ACE inhibitor 4368 (47.9) 1026 (36.8) 2378 
(56.6) 
551 
(54.0) 
413 
(37.6) 
Angiotensin 
receptor blocker 
2664 (29.2) 1028 (36.9) 1021 
(24.3) 
178 
(17.5) 
437 
(39.7) 
Statins 8453 (92.8) 2598 (93.1) 3894 
(92.7) 
938 
(92.0) 
1023 
(93.0) 
Other lipid 
lowering drug 
855 (9.4) 272 (9.8) 304 (7.2) 159 
(15.6) 
120 
(10.9) 
Diuretics 2318 (25.4) 581 (20.8) 1190 
(28.3) 
271 
(26.6) 
276 
(25.1) 
Antidepressants 640 (7.0) 101 (3.6) 285 (6.8) 172 
(16.9) 
82 (7.5) 
All numbers are given as numbers (%) 
ACE=Angiotensin Converting Enzyme 
Health Care Resource Utilization and Status 
Health care resource utilization in the 6 months prior to enrolment included at 
least one visit to a cardiologist (31.7%), other specialist (7.7%), general practitioner or 
family physician (19.6%), or emergency room (5.8%).  Hospitalization necessitating at 
least an overnight stay occurred in the previous 6 months in 5.4% for a cardiovascular 
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(4.8%) or bleeding (0.7%) event (including coronary angiography), with a median length 
of stay of 4 (2, 7) days.   
Self-reported health status by EQ-5D assessment was available at baseline in 
9,177 (99.5%) of patients, and limitations were identified with: mobility (24.7%), self-
care (5.8%), usual activities (18.5%), pain/discomfort (36.0%), and anxiety/depression 
(22.8%).  Overall health status measured by EQ-Index score was a median of 0.85 
(scale from 0 to 1), and by EQ-VAS score was 80 (70, 90)(scale from 1-100). 
 
DISCUSSION 
 This report provides unique contemporary enrolment data on the patient 
characteristics, treatment patterns, CV-related healthcare resource utilization, and 
quality of life in stable high-risk CAD patients 1-3 years post-MI from different 
geographical regions (25 countries) in routine clinical practice.  At a median of 1.8 years 
after an MI, approximately 1 in 7 patients are current smokers, 2 in 3 are overweight or 
obese, and 1 in 4 had a blood pressure of ≥140/90 mm Hg.  Regarding medication use, 
almost all patients were on at least one antithrombotic drug and a statin and/or other 
lipid-lowering therapy, and 8 in 10 were on beta-blocker and an ACE inhibitor or 
angiotensin receptor blocker. Specifically regarding antiplatelet therapy, we observed 
that 1 in 4 post-MI patients with ≥1 atherothrombotic risk factor did not receive DAPT for 
~1 year.  Further, in contrast to randomized clinical trial evidence and some 
international guideline recommendations supporting newer ADPris in the majority of 
these patients, clopidogrel was mainly prescribed as part of DAPT.  Interestingly, prior 
to recent randomized trial data supporting DAPT >1 year post-MI/PCI, >1 in 4 patients 
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have continued on DAPT, though with substantial international variability.  Health care 
resource utilization in the 6 months prior to enrolment included a visit to a physician or 
emergency room for approximately 1 in 5, and hospitalization for a CV or bleeding event 
for 1 in 20 patients.  Despite some issues for the five dimensions (mobility [25%], self-
care [5%], usual activities [19%], pain/discomfort [36%], anxiety/depression [23%]) of 
self-reported quality of life, overall health status is perceived as similar to that in a 
general age- and sex-matched U.K. population without cardiovascular disease.23   
While the study specifically includes patients at least 50 years of age with 
additional high risk features, such as those ≥65 years (63%, with 20% ≥75 years), those 
with multivessel disease (66%), diabetes mellitus requiring medication (30%), a second 
prior MI >1 year ago (10%), or chronic, non-end stage renal dysfunction (8%), more 
than half (55%) have more than one of the qualifying, prognostically important factors.  
The older population (median 67 years) likely accounts for the majority (62%) being 
retired or on sick leave/disability.  The higher proportion (52%) of STEMI patients and 
those who underwent coronary revascularization (88%) as part of the index MI 
management likely reflects the fact that the vast majority of recruiting physicians were 
cardiologists.  Similarly, the majority of the TIGRIS population lives in a metropolitan 
area (65%) with an annual income (among those reported) of ≥$15,000 U.S. (51%).    
There was evidence of regional differences, such as lower frequencies of obesity 
in Asia-Pacific compared to other regions, and lower rates of utilization of antithrombotic 
therapies and beta-blockers in Asia-Pacific, but higher rates of DAPT >1 year post-MI. 
ACE inhibitor or ARB use was highest in Europe and lowest in North America.  One 
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possible explanation for higher continued use of DAPT in Asia-Pacific relates to the 
higher observed use of prior PCI in this region. 
While the laboratory values available were limited arbitrarily by a 4 month window 
around the time of enrolment and were not study-wide given the capture of clinically 
obtained measures only, the proportion of patients with LDL-cholesterol above some 
(but not all) international guideline-recommended target(s) was approximately 60%, 
despite 93% of these patients receiving statin and/or other lipid-modifying therapy. 
Consistent with several international guideline recommendations, and another 
earlier (2010-11) prospective observational international study of ACS hospital 
survivors,24 approximately 75% of patients received dual antiplatelet therapy (DAPT) as 
an integral part of their index MI management, particularly in the setting of frequent PCI 
with stenting, for approximately 1 year post.  However, in contrast to some guideline 
recommendations25-27 and RCT evidence suggesting superiority of the newer ADP 
receptor inhibitors prasugrel9 or ticagrelor,10 clopidogrel was prescribed instead.  Of 
interest, preceding more recent RCT data supporting DAPT beyond 1 year’s time post-
MI/PCI with stenting,13;28-30 27% of our cohort have been continued on DAPT for at least 
a median of 1.6 years until the time of enrolment into TIGRIS.  
Limitations 
 A number of limitations are relevant to our study.  First, principal investigator/site 
selection was not random or specifically population-based and predominantly consisted 
of cardiologists who were invited and chose to participate, were more likely to have 
resources to facilitate patient enrollment, data collection, and study follow-up, and are 
therefore not likely representative of routine non-specialist clinical practice.  Second, 
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while consecutive patient selection was encouraged, TIGRIS is a prospective 
observational study with specific inclusion criteria (e.g., stable patients 1-3 years post-
MI, age of at least 50 years, high risk features such as multivessel CAD, requirement for 
informed consent) that, while less selected than a typical RCT, resulted in a cohort that 
is not representative of all post-MI survivors.  Third, information regarding the use of 
antecedent and current medications is based upon medical record information and does 
not address actual patient adherence.  Fourth, we noted variations in patient 
characteristics, treatment/management, and non-adjudicated/systematically validated 
CV events in different geographic regions; however, the participating physicians reflect 
regional specialist practices and but do not necessarily reflect practice for specific 
countries.  Fifth, despite enrolling patients from 25 countries in most continents, we did 
not have representation from Africa and only 1% were black.  Sixth, it is challenging to 
compare our data with other contemporary large-scale observational studies (e.g., the 
Prospective Observational Longitudinal Registry of Patients With Stable Coronary 
Artery Disease [CLARIFY]31) as each employs unique (with some overlapping) inclusion 
criteria to identify their coronary artery disease (stable vs. acute) cohort.  Seventh, as 
ticagrelor did not have an indication for use >1 year post-MI when TIGRIS prospectively 
enrolled patients 1-3 after the index MI, patients receiving ticagrelor would have been 
excluded from the cohort. 
 
CONCLUSIONS 
 Approximately 2 years after a MI, atherothrombotic risk factor (e.g., smoking, 
obesity, hypertension, dyslipidemia) modification in a large international cohort remains 
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suboptimal.  However, the vast majority of patients were receiving evidence-based 
medical therapies, including antithrombotic, beta-blocker, ACE inhibitor or angiotensin 
receptor blocker, and statin drug(s).  Further, despite some issues for the five 
dimensions of self-reported quality of life, overall health status was perceived as 
relatively high in this population.  Consistent with guideline recommendations, patients 
received DAPT for approximately 1 year post-MI; however, in contrast to RCT evidence 
supporting newer ADPris, clopidogrel was mainly prescribed post-index MI.  Preceding 
recent RCT data supporting DAPT >1 year’s time post-MI/PCI, more than 1 in 4 patients 
have continued DAPT though with substantial international variability.  These findings 
represent an opportunity to further improve upon routine antithrombotic management of 
post-MI patients.   
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Figure 1. Antithrombotic Therapy at Enrolment 
 
Antithrombotic therapy at enrolment (median 1.8 years post-myocardial infarction), 
including acetylsalicylic acid (ASA) only, adenosine diphosphate receptor inhibitor 
(ADPri) only, dual antiplatelet therapy (DAPT), and oral anticoagulant (OAC) therapy, 
for the overall population and by region. 
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